Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.56 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.48 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.48 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.48 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.95 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28303526 | 1.00 | TAAR1 (0.95) | TAAR1HTR2AAOC3TRPA1SLC6A2 | |
| Hydrochloric Acid SCHEMBL28303473 | 1.00 | TAAR1 (0.95) | TAAR1HTR2AAOC3TRPA1SLC6A2 | |
| SCHEMBL238388 | 0.97 | TAAR1 (1.00) | TAAR1HTR2AAOC3TRPA1RIPK1 | |
| SCHEMBL240503 | 0.97 | TAAR1 (1.00) | TAAR1HTR2AAOC3TRPA1RIPK1 | |
| SCHEMBL2107 | 0.97 | TAAR1 (1.00) | TAAR1HTR2AAOC3TRPA1RIPK1 | |
| Bromide SCHEMBL29883460 | 0.95 | TAAR1 (0.95) | TAAR1HTR2AAOC3TRPA1RIPK1 | |
| Bromide SCHEMBL28358414 | 0.95 | TAAR1 (0.95) | TAAR1HTR2AAOC3TRPA1RIPK1 | |
| SCHEMBL28569125 | 0.89 | TAAR1 (0.83) | TAAR1HTR2AAOC3TRPA1RIPK1 | |
| SCHEMBL1930994 | 0.89 | TAAR1 (0.83) | TAAR1HTR2AAOC3TRPA1RIPK1 | |
| SCHEMBL28569127 | 0.89 | TAAR1 (0.83) | TAAR1HTR2AAOC3TRPA1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111217741-A | Fluorine-substituted monocarbazole derivative, preparation method and application thereof | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2020-06-02 | — | — | CN | claimed |
| CN-117820236-A | Histone acetyltransferase small molecule inhibitor and preparation method and application thereof | 复旦大学 | 2024-04-05 | — | — | CN | disclosed |
| CN-109942499-B | Quinazoline derivative and preparation method and application thereof | 湖南中医药大学 | 2022-03-22 | — | — | CN | disclosed |
| CN-111217741-B | Fluorine-substituted monocarbazole derivative, preparation method and application thereof | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2022-03-15 | — | — | CN | disclosed |
| CN-111217741-A | Fluorine-substituted monocarbazole derivative, preparation method and application thereof | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2020-06-02 | — | — | CN | disclosed |
| CN-109942499-A | Quinazoline derivant and its preparation method and application | 湖南中医药大学 | 2019-06-28 | — | — | CN | disclosed |
| US-9328125-B2 | Bivalent AMPA receptor positive allosteric modulators | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150057248-A1 | BIVALENT AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-02-26 | — | — | US | disclosed |
| US-8476297-B2 | TRP-M8 receptor ligands and their use in treatments | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| EP-2571880-A1 | PYRROLO [2, 3 - B]PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-27 | — | — | EP | disclosed |
| CN-1429204-A | Process for producing biphenyl compound | LILLY CO ELI (US) | 2003-07-09 | — | — | CN | disclosed |
| CN-1429206-A | Sulfonamide derivatives | LILLY CO ELI (US) | 2003-07-09 | — | — | CN | disclosed |
| CN-1429205-A | Sulfonamide derivatives | ELILILLY AND COMPANY (US) | 2003-07-09 | — | — | CN | disclosed |
| US-20030092770-A1 | Combination therapy for treatment of depression | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
| US-20030092947-A1 | Process for preparing biphenyl compounds | GARDNER JOHN PAUL (US) | 2003-05-15 | — | — | US | disclosed |
| US-6300501-B1 | Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase | WARNER-LAMBERT COMPANY | 2001-10-09 | — | — | US | disclosed |
| EP-0938494-A1 | INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1997044350-A1 | INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1997-11-27 | — | — | WO | disclosed |
| CN-1011780-B | PROCESS FOR PRODUCING PHENOXYACETIC ACID DERIVATIVES | TANABE SEIYAKU CO (JP) | 1991-02-27 | — | — | CN | disclosed |
| CN-87105501-A | New phenoxyacetic acid derivative and preparation method thereof and contain its and form as the medicine of activeconstituents | — | 1988-02-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092770-A1 | Combination therapy for treatment of depression | GRM2, GRIK2, GRIN2A | HTR2A 105/4885SLC6A2 113/4885SLC6A4 106/4885 |
| US-20030092947-A1 | Process for preparing biphenyl compounds | CYP1B1, CYP4B1, CYP2B6 | HTR2A 1777/4885SLC6A2 1195/4885SLC6A4 1605/4885 |
| US-20150057248-A1 | BIVALENT AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATORS | GRIK2, GABRE, GRIK4 | HTR2A 373/4885SLC6A2 1436/4885SLC6A4 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.